184 related articles for article (PubMed ID: 3312013)
21. Studies with a new generation of oral attenuated shigella vaccine: Escherichia coli bearing surface antigens of Shigella flexneri.
Levine MM; Woodward WE; Formal SB; Gemski P; DuPont HL; Hornick RB; Snyder MJ
J Infect Dis; 1977 Oct; 136(4):577-82. PubMed ID: 333041
[TBL] [Abstract][Full Text] [Related]
22. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers.
Metzger WG; Mansouri E; Kronawitter M; Diescher S; Soerensen M; Hurwitz R; Bumann D; Aebischer T; Von Specht BU; Meyer TF
Vaccine; 2004 Jun; 22(17-18):2273-7. PubMed ID: 15149786
[TBL] [Abstract][Full Text] [Related]
23. Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a.
Tacket CO; Forrest B; Morona R; Attridge SR; LaBrooy J; Tall BD; Reymann M; Rowley D; Levine MM
Infect Immun; 1990 Jun; 58(6):1620-7. PubMed ID: 1692807
[TBL] [Abstract][Full Text] [Related]
24. A review of the current status of enteric vaccines.
Levine MM; Noriega F
P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
[TBL] [Abstract][Full Text] [Related]
25. Enteroadhesion fimbriae and enterotoxin of Escherichia coli: genetic transfer to a streptomycin-resistant mutant of the galE oral-route live-vaccine Salmonella typhi Ty21a.
Yamamoto T; Tamura Y; Yokota T
Infect Immun; 1985 Dec; 50(3):925-8. PubMed ID: 3905619
[TBL] [Abstract][Full Text] [Related]
26. Core-linked LPS expression of Shigella dysenteriae serotype 1 O-antigen in live Salmonella Typhi vaccine vector Ty21a: preclinical evidence of immunogenicity and protection.
Xu DQ; Cisar JO; Osorio M; Wai TT; Kopecko DJ
Vaccine; 2007 Aug; 25(33):6167-75. PubMed ID: 17629369
[TBL] [Abstract][Full Text] [Related]
27. Live recombinant Salmonella Typhi vaccines constructed to investigate the role of rpoS in eliciting immunity to a heterologous antigen.
Shi H; Santander J; Brenneman KE; Wanda SY; Wang S; Senechal P; Sun W; Roland KL; Curtiss R
PLoS One; 2010 Jun; 5(6):e11142. PubMed ID: 20585446
[TBL] [Abstract][Full Text] [Related]
28. Construction of a stable and non-resistant bivalent vaccine candidate strain against Shigella flexneri 2a and Shigella sonnei.
Rui X; Xu Y; Wan H; Su G; Huang C
Chin J Biotechnol; 1996; 12(2):89-97. PubMed ID: 8988355
[TBL] [Abstract][Full Text] [Related]
29. Safety and antigenicity of typhoid-Shigella sonnei vaccine (strain 5076-1C).
Tramont EC; Chung R; Berman S; Keren D; Kapfer C; Formal SB
J Infect Dis; 1984 Feb; 149(2):133-6. PubMed ID: 6366077
[TBL] [Abstract][Full Text] [Related]
30. Isoenzyme analysis of typhoid-Shigella and Escherichia-Shigella hybrid vaccines and their parental strains.
Schultz C
J Clin Microbiol; 1989 Dec; 27(12):2838-41. PubMed ID: 2687324
[TBL] [Abstract][Full Text] [Related]
31. In vivo evidence of immunological masking of the Vibrio cholerae O antigen of a hybrid Salmonella typhi Ty21a-Vibrio cholerae oral vaccine in humans.
Forrest BD; LaBrooy JT
Vaccine; 1991 Jul; 9(7):515-20. PubMed ID: 1716810
[TBL] [Abstract][Full Text] [Related]
32. Strategy for cross-protection among Shigella flexneri serotypes.
Noriega FR; Liao FM; Maneval DR; Ren S; Formal SB; Levine MM
Infect Immun; 1999 Feb; 67(2):782-8. PubMed ID: 9916090
[TBL] [Abstract][Full Text] [Related]
33. Vi Capsular Polysaccharide Produced by Recombinant
Xiong K; Zhu C; Chen Z; Zheng C; Tan Y; Rao X; Cong Y
Front Cell Infect Microbiol; 2017; 7():135. PubMed ID: 28484685
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of two Salmonella typhimurium hybrids as challenge organisms in a system for the assay of typhoid vaccines.
Johnson EM; Diena BB; Lior H; Ryan A; Krol P; Baron LS
Infect Immun; 1982 Oct; 38(1):201-5. PubMed ID: 6754614
[TBL] [Abstract][Full Text] [Related]
35. [Expression of S.sonnei form I antigen gene and V.cholerae toxin B subunit gene in S.flexneri 2a strain and investigation of their immunoprotective response in mice].
Qian F; Rui X; Su G; Huang C
Yi Chuan Xue Bao; 1996; 23(4):322-8. PubMed ID: 8950856
[TBL] [Abstract][Full Text] [Related]
36. Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection.
Altboum Z; Barry EM; Losonsky G; Galen JE; Levine MM
Infect Immun; 2001 May; 69(5):3150-8. PubMed ID: 11292735
[TBL] [Abstract][Full Text] [Related]
37. Use of the alpha-hemolysin secretion system of Escherichia coli for antigen delivery in the Salmonella typhi Ty21a vaccine strain.
Gentschev I; Dietrich G; Spreng S; Neuhaus B; Maier E; Benz R; Goebel W; Fensterle J; Rapp UR
Int J Med Microbiol; 2004 Oct; 294(6):363-71. PubMed ID: 15595386
[TBL] [Abstract][Full Text] [Related]
38. Auxotrophic live oral Shigella flexneri vaccine protects monkeys against challenge with S. flexneri of different serotypes.
Kärnell A; Sweiha H; Lindberg AA
Vaccine; 1992; 10(3):167-74. PubMed ID: 1557932
[TBL] [Abstract][Full Text] [Related]
39. Live attenuated Salmonella Typhimurium with monophosphoryl lipid A retains ability to induce T-cell and humoral immune responses against heterologous polysaccharide of Shigella flexneri 2a.
Liu Q; Su H; Bian X; Wang S; Kong Q
Int J Med Microbiol; 2020 Jul; 310(5):151427. PubMed ID: 32654768
[TBL] [Abstract][Full Text] [Related]
40. Cross-reactive immune response elicited by parenteral Vi polysaccharide typhoid vaccine against non-typhoid Salmonellae.
Pakkanen SH; Kantele JM; Herzog C; Kantele A
Vaccine; 2014 Jan; 32(5):544-51. PubMed ID: 24342246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
